Clinical trials: Recurrent Epithelial Ovarian Cancer
Recurrent Ovarian Cancer, Fallopian Tube Carcinoma
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Conditions
- Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01381861
- Testing
- Carotuximab (TRC105)
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Recurrent, Platinum-resistant Ovarian Cancer
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
Multicenter Phase II study on Decitabine-Carboplatin combination in platinum resistant ovarian cancer patients. Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances…
- Trial name
- MITO29 (NCT03467178)
- Testing
- Decitabine, Carboplatin, Pegylated Liposomal Doxorubicin
- Where
- Italy
- Volunteers
- 119 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Ovarian Cancer, Recurrent Ovarian Cancer
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.
- Trial name
- NCT07714668
- Testing
- SYS6041, bevacizumab, SYS6041, carboplatin, bevacizumab, paclitaxel, carboplatin, bevacizumab
- Where
- China
- Volunteers
- 171 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Ovarian Cancer
Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer
The purpose of this study is to validate a score developed by the AGO-OVAR for complete resection of the tumor
- Trial name
- NCT00368420
- Where
- 12 sites in Austria, Belgium and 2 more
- Volunteers
- 122 people
- Sponsor
- AGO Study Group
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment.
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03026062
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Extragonadal Germ Cell Tumor, Ovarian Cancer
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002903
- Testing
- docetaxel
- Where
- 49 sites in Austria, Belgium and 12 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer, Epithelial
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT05422183
- Testing
- Envafolimab, Lenvatinib, VP-16
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I clinical trial studies the side effects of vaccine therapy and cyclophosphamide in treating patients with stage II-III breast cancer or stage II-IV ovarian, primary peritoneal or fallopian tube cancer.
- Conditions
- Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01606241
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Cervical Cancer, Endometrial Cancer
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00287885
- Testing
- docetaxel
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00005858
- Testing
- LMB-9 immunotoxin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Ovarian Neoplasms, Uterine Neoplasms
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
The primary aim of this study is: To determine the overall clinical response rate of weekly Topotecan and Taxotere in women with recurrent ovarian, primary peritoneal, endometrial and uterine cancers.
- Trial name
- NCT00231855
- Testing
- Topotecan and Taxotere
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Montefiore Medical Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ovarian Cancer, Recurrent Ovarian Cancer
HERCULES: Ultrasound-Based Liver Involvement Classification in Ovarian Cancer
This monocentric observational pilot study aims to assess the feasibility of a standardized two-dimensional ultrasound (2D US) approach for the preoperative assessment and anatomo-surgical classification of liver-area involvement…
- Trial name
- HERCULES (NCT07808320)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Quality of Life, Ovarian Cancer
QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.
- Conditions
- Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
- Trial name
- COMPASS (NCT03164980)
- Testing
- Trabectidin (Yondelis)
- Where
- 21 sites in Germany
- Volunteers
- 89 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression
- Trial name
- NCT00408967
- Testing
- Tucotuzumab celmoleukin (EMD 273066)
- Sponsor
- EMD Serono
Breast Cancer, Esophageal Cancer
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT01172028
- Testing
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Arizona
Ovarian Cancer
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective…
- Trial name
- NCT00019136
- Testing
- MOv-gamma chimeric receptor gene, aldesleukin, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
This phase II trial is studying how well vorinostat works in treating patients with recurrent or persistent ovarian epithelial or primary peritoneal cavity cancer.
- Trial name
- NCT00132067
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Gynecological Cancer, Metastatic Cervical Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer.
- Conditions
- Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer
- Trial name
- NCT03277482
- Testing
- Durvalumab, Tremelimumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.